Narcotic Analgesics

Pediatric Analgesia: Facilitating Clinical Trials

A multicenter pediatric pain clinical trials consortium will facilitate better study design and ensure children experience no additional burden for participation in research, including enduring even slightly undertreated pain, a panel of pediatric pain experts said during the American Pain Society’s 30th Annual Scientific Meeting.

Assessment of Methadone on the QTc-Interval Prolongation

Controversy surrounds the issue of methadone-induced QTc-interval prolongation (QTcP or torsades de pointes), and just who should have EKG testing and when. According to study results presented at the American Pain Society’s 30th Annual Scientific Meeting, there is a dose-dependent effect on QTcP in patients taking <120mg/day of methadone compared with lower doses.

Abstral Available for Breakthrough Cancer Pain

ProStrakan Group announced the availability of Abstral (fentanyl) sublingual tablets as the first rapidly-disintegrating tablet placed under the tongue for breakthrough cancer pain.

King Pharmaceuticals Recalls Embeda

King Pharmaceuticals, a subsidiary of Pfizer, announced a voluntary recall of all lots of Embeda (morphine/naltrexone extended-release capsules) because Embeda did not meet a prespecified stability requirement during routine testing.